Rituxan (rituximab) - Roche
EFFICACY AND SAFETY OF SPLENECTOMY IN PRIMARY ITP IN THE MODERN ERA: A GIMEMA STUDY (SIE 2026) - Oct 6, 2026 - Abstract #C079; Pres time: Sep 22, 2026; 03:40 PM - 05:10 PM; Location: HALL 4; "ITP therapy was administered in all pts, mostly corticosteroids (CS) (86%), IVIG (49%), TPO RAs (30%) and rituximab (12%)...Conclusions. This contemporary Italian real world cohort confirms that splenectomy achieves high response rates with a low incidence of complications, supporting its contin- ued role in selected pts with ITP." 
Clinical • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Infectious Disease • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis
https://manage.ercongressi.it/storage/ercongressi/article/pdf/291/14496-SIE2026%20-%20abstract%20book.pdf
 
F. Palandri1; C. Sartor1; C. La Torella2; F. Branzanti3; L. Gorreo Renzulli2; M. Carpenedo4; G. Carli5; O. Mulas6; E. Lucchini7; V. Carrai8; U. Consoli9; V. De Stefano10; G. Auteri11; C. Santoro12; N. Vianelli1; A. Piciocchi2; F. Zaja7,13
 
Oct 6, 2026
 
Prev Next